Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases. Increasing the expression level or inducing the activity of LDLR in hepatocyte...

Full description

Saved in:

Bibliographic Details
Main Authors:	Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-09-01
Series:	Tzu Chi Medical Journal
Subjects:	atherosclerotic cardiovascular diseases hypercholesterolemia low-density lipoprotein receptor proprotein convertase subtilisin/kexin type 9 phytochemicals
Online Access:	https://journals.lww.com/10.4103/tcmj.tcmj_46_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
by: Hongyan Jiang, et al.
Published: (2024-12-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

Subtilisin/kexin type 9 protein convertase and interleukin 1 beta alterations in acute myocardial infarction
by: Michał Majewski, et al.
Published: (2025-05-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9
by: Chan Joo Lee, et al.
Published: (2025-09-01)

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
by: Haixia Tang, et al.
Published: (2025-08-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
by: Antonio J. Vallejo‐Vaz, et al.
Published: (2018-09-01)

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
by: Gregory P. Geba, et al.
Published: (2024-12-01)

The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection
by: Omer Qutaiba B. Allela, et al.
Published: (2024-12-01)

Outpatient Practice of Lipid-Lowering Therapy Prescription (According to the ARGO-3 Study)
by: M. V. Ezhov, et al.
Published: (2023-05-01)

Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024-11-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Human PCSK9D374Y exacerbates methionine choline deficiency diet-induced nonalcoholic steatohepatitis in mice
by: Abidan·ABUDURUSULI, CHEN Xiaocui, CUI Yuanfeng, Tuoluonayi·MIJITI, DENG Lihui, CHEN Bangdang
Published: (2025-05-01)

Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects
by: Ajoy Basak
Published: (2025-03-01)

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review
by: Fang Jia, et al.
Published: (2025-01-01)

Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9
by: Marcella Palumbo, et al.
Published: (2025-03-01)

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus
by: Zhicai Feng, et al.
Published: (2023-12-01)

PCSK9 promotes T helper 1 and T helper 17 cell differentiation by activating the nuclear factor‐κB pathway in ankylosing spondylitis
by: Jianfei Cai, et al.
Published: (2023-05-01)

Modified Diagnostic Criteria Tools for Familial Hypercholesterolemia without the Requirement for Clinical Genetic Testing: Rationale and Design of the MOOCS Adaptive Clinical Trial
by: Satyanarayana Upadhyayula
Published: (2024-10-01)

Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
by: Xi Li, et al.
Published: (2025-02-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Atherosclerosis and inflammation: therapeutic targets and ways of correction
by: A. A. Klimenko, et al.
Published: (2024-06-01)

Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single‐Arm Study
by: Weiqi Zeng, et al.
Published: (2025-01-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
by: Rishi Rikhi, et al.
Published: (2023-06-01)

Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective
by: Tinh-Hai Collet, et al.
Published: (2024-12-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Association of circulating proprotein convertase subtilisin/kexin type 9 concentration with coagulation abnormalities in patients with primary membranous nephropathy
by: Huizi Zhu, et al.
Published: (2023-12-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors
by: Fahui Li, et al.
Published: (2022-12-01)

The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus
by: Jun-Xu Gu, et al.
Published: (2025-03-01)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)

Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease
by: Angelika Hettenbach, et al.
Published: (2025-03-01)

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis
by: Bohan Luo, et al.
Published: (2025-08-01)

Elevated levels of lipoprotein(a) and low-density lipoprotein cholesterol in familial hypercholesterolemia patients: is dual primary prevention already in sight?
by: Alpo Vuorio, et al.
Published: (2025-07-01)